Invivyd Appoints New CMO and COO
Ticker: IVVD · Form: 8-K · Filed: May 31, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
Invivyd beefs up exec team with new CMO & COO, watch for new strategies.
AI Summary
Invivyd, Inc. announced on May 30, 2024, the appointment of Dr. Patrick Gilmore as Chief Medical Officer and Dr. David Apelian as Chief Operating Officer. The company also disclosed compensatory arrangements for these officers, including base salaries and potential bonuses, as part of its ongoing operations in the biological products sector.
Why It Matters
The appointment of key executive roles like Chief Medical Officer and Chief Operating Officer can signal strategic shifts or growth phases for a biotechnology company, impacting its research, development, and operational execution.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and execution, while the nature of compensatory arrangements may also warrant scrutiny.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Dr. Patrick Gilmore (person) — Appointed Chief Medical Officer
- Dr. David Apelian (person) — Appointed Chief Operating Officer
- May 30, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Invivyd, Inc.?
Dr. Patrick Gilmore has been appointed as the new Chief Medical Officer of Invivyd, Inc.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 30, 2024.
Who has been appointed as the new Chief Operating Officer of Invivyd, Inc.?
Dr. David Apelian has been appointed as the new Chief Operating Officer of Invivyd, Inc.
What is the principal executive office address for Invivyd, Inc.?
The principal executive office address for Invivyd, Inc. is 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the SIC code for Invivyd, Inc.?
The Standard Industrial Classification (SIC) code for Invivyd, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,051 words · 4 min read · ~4 pages · Grade level 10.1 · Accepted 2024-05-31 07:12:34
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- d831636d8k.htm (8-K) — 30KB
- d831636dex991.htm (EX-99.1) — 20KB
- d831636dex992.htm (EX-99.2) — 22KB
- g831636dsp9.jpg (GRAPHIC) — 4KB
- g831636page1a.jpg (GRAPHIC) — 3KB
- 0001193125-24-151007.txt ( ) — 223KB
- ivvd-20240530.xsd (EX-101.SCH) — 3KB
- ivvd-20240530_lab.xml (EX-101.LAB) — 18KB
- ivvd-20240530_pre.xml (EX-101.PRE) — 11KB
- d831636d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 31, 2024 99.2 Press Release, dated May 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: May 31, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary